Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Inclusion Criteria:

• Patients with AML, a certain type of ALL, NHL and MM
• certain types of cancer of the lymph nodes
• certain types of leukemias (blood cancers)
• disease has or will fail with other treatments
• relatively good overall health other than your cancer

Exclusion Criteria:

• poor bone marrow function (not producing enough blood cells)
• serious heart conditions
• poor liver or kidney function